Andrew W. Hahn, MD, presented “Cardiometabolic Health for Men with Advanced Prostate Cancer: Lessons Learned and Future Directions” during the 34th International Prostate Cancer Update on February 13, 2024, in Vail, Colorado.
This content is available free to the GRU Community. Login or create an account to view it.
How to cite: Hahn, Andrew W. “Cardiometabolic Health for Men with Advanced Prostate Cancer: Lessons Learned and Future Directions.” February 2024. Accessed Dec 2024. https://grandroundsinurology.com/cardiometabolic-health-for-men-with-advanced-prostate-cancer-lessons-learned-and-future-directions/
Cardiometabolic Health for Men with Advanced Prostate Cancer: Lessons Learned and Future Directions – Summary
Andrew W. Hahn, MD, addresses cardiometabolic health in men with advanced prostate cancer, focusing on the impacts of hormone therapy and strategies for managing cardiovascular risks.
In this 10-minute talk, Dr. Hahn highlights the common overlap of prostate cancer and cardiometabolic risk factors and underscores the necessity of evaluating cardiovascular risk in prostate cancer patients. He reviews data indicating that androgen deprivation therapy (ADT) can indirectly increase cardiovascular risks by altering body composition and intensifying metabolic syndrome. Adding androgen receptors nearly doubles cardiovascular event risk. Despite FDA advisories, guidelines, and the availability of cardiovascular risk assessments, many patients undergoing ADT lack appropriate cardiovascular monitoring.
Dr. Hahn highlights future directions in identifying men at heightened risk for cardiovascular events using imaging and genomic biomarkers. Promising approaches include myocardial perfusion PET scans and exploring genomic markers that correlate with cardiovascular toxicity in hormone therapy. Managing cardiometabolic health in advanced prostate cancer requires careful risk assessment and personalized approaches. Biomarkers are needed to effectively predict cardiovascular complications from hormone therapy.
About The 34th Annual International Prostate Cancer Update:
The International Prostate Cancer Update (IPCU), founded in 1990, is a multi-day CME conference focused on prostate cancer treatment updates with expert, international faculty. It is led by expert physicians and is designed for urologists, medical oncologists, radiation oncologists, and other healthcare professionals involved in the diagnosis and treatment of prostate cancer. The 34th iteration of the meeting occurred February 11-14, 2024 in Vail, Colorado. To view more educational presentations from IPCU 34, visit our collection page.
ABOUT THE AUTHOR
Dr. Andrew Hahn is an Assistant Professor of Genitourinary Medical Oncology at MD Anderson Cancer Center. Andrew earned a Bachelor of Arts in Synthetic Medicinal Chemistry and his Medical Doctorate at the University of Tennessee. Dr. Hahn completed Internal Medicine residency and a Chief Medicine Resident year at the University of Utah followed by his Medical Oncology fellowship at MD Anderson Cancer Center. His clinical focus is on prostate and kidney cancers. His research focus is to investigate how host factors influence response, resistance, and toxicity to cancer treatments and to design and run clinical trials to improve outcomes for patients with prostate and kidney cancer. Dr. Hahn has published over 40 peer-reviewed original research articles and authored or co-authored 30 other editorials, reviews, and book chapters. His work has been supported by an ASCO Conquer Cancer Foundation Young Investigator Award, Prostate Cancer Foundation Young Investigator Award, and a Department of Defense Early Investigator Research Award.
